Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
Meiying Wang†1, Hongsheng Sun†1, Wei Zhang2 and Yuanchao Zhang*1

Address: 1Department of Rheumatology and Immunology, Provincial Hospital affiliated to Shandong University, Jinan, 250021, China and 2Department of Pain Management, Hospital affiliated to Medical College of Qingdao University, Qingdao, 266003, China
Email: Meiying Wang - wmy99wmy99@yahoo.cn; Hongsheng Sun - sunhongsheng.shs@126.com; Wei Zhang - zw99zw99@126.com; Yuanchao Zhang* - sdfs2004@sohu.com
* Corresponding author †Equal contributors

Abstract

Background: Systemic lupus erythematosus (SLE) is a representative systemic autoimmune disease characterized by activated T cells and polyclonally activated B cells that produce autoantibodies. Activation of autoreactive T and B cells plays a pivotal role in the pathogenesis of this disease. A role of focal adhesion kinase (FAK) in the pathogenesis has been suggested. Proline-rich tyrosine kinase2 (PYK2) is structurally related to FAK, however, the functional activation of PYK2 in SLE remains unclear. In the present study, we showed that PYK2 is significantly increased and activated in peripheral blood mononuclear cells (PBMCs) of patients with SLE. In addition, we showed the involvement of PYK2 proteins in the up-regulation of CD40L and CTLA4 expression and PBMC proliferation.

Methods: Freshly isolated PBMCs from 48 SLE patients, 32 patients with rheumatoid arthritis (RA) and 24 healthy individuals were analyzed for the expression and activation of PYK2 by western-blotting and immunocytochemistry. The other isolated PBMCs from patients with this condition were cultured and stimulated with PMA or TyrA9, and then the expression of costimulatory molecules CD40L and CTLA4 was evaluated using flow cytometry, PBMCs proliferation was determined with [3H]-thymidine incorporation (CPM).

Results: Compared with RA patients and healthy donors, PBMCs from SLE patients expressed more of both the total PYK2 protein and its activated/phosphorylated form. The increase of activated PYK2 protein in SLE PBMCs was correlated with the complication of nephritis and inversely associated the level of serum complements. In active SLE patients, activation of PYK2 in PBMCs is accompanying the increased cell proliferation and the induced expression of costimulatory molecules CD40L and CTLA4.

Conclusion: Our findings indicate that phosphorylated PYK2 in SLE PBMCs may induce the expression of CD40L and CTLA4, and subsequently the cell proliferation. PYK2 signaling enhances the autoreactive lymphocyte activation and plays an important role in the pathogenesis of SLE.
Background
Systemic lupus erythematosus (SLE) is a representative systemic autoimmune disease characterized by activated T cells and polyclonally activated B cells that produce autoantibodies. Activation of autoreactive T and B cells plays a pivotal role in the pathogenesis of this disease [1,2]. Although SLE T cells have impaired interleukin-2 (IL-2) production and proliferative response to stimulation of the T cell receptor-CD3 compound[3,4], expression of costimulatory molecules such as CD40L and CTLA4, which is essential for lymphocyte activation [5,6], is up-regulated [7-10]. These molecules are thus targets in considering effective strategies in the treatment of SLE. Lupus mice treated with antibody against CD40L or CTLA4-Ig have lower level of anti-doublestranded DNA antibodies, later development of nephritis, and prolonged survival time [11-13]. In patients with SLE, the reduced expression of CD28 costimulatory molecule on both CD4- and CD8-T cells is also well documented [14,15]. CD28-mediated costimulatory activity, following the interaction of T cells with B cells, is significantly decreased in patients with SLE [14]. Thus, it seems that costimulatory signals in SLE T cells may differ from those present in normal T cells.

Lately, in SLE T cells, focal adhesion kinase (FAK) have been shown to be involved in costimulatory molecule expression and cell proliferation[16]. Similar findings regarding the involvement of FAK were also reported in other inflammation-related diseases, such as rheumatoid arthritis (RA)[17,18], diabetes[19], chronic inflammatory bowel diseases[20] and asthma[21]. It is thus likely that FAK may represent a new molecular target for the anti-inflammatory treatment.

The proline-rich tyrosine kinase 2 (PYK2) is a nonreceptor protein tyrosine kinase that is structurally related to FAK [22]. It is also known as cell adhesion kinase-β or related adhesion focal tyrosine kinase. Unlike the ubiquitous expression of prototype FAK, PYK2 is primarily expressed in populations of neuronal and hematopoietic cells[23]. PYK2 becomes activated in response to stimulation through a number of receptors, of which include integrins[24,25], cytokine receptors [26-28] and lymphocyte antigen receptors [29-31]. Numerous studies over the years have shown that PYK2 provides important signals during the activation of lymphocytes [32-35]. However, in SLE, PYK2’s expression and activation in PBMCs, as well as the functional significance of PYK2 in T cell and B cell activation, remains unclear.

In this study, we showed that PYK2 is significantly increased and activated in PBMCs of patients with active SLE. In addition, we showed the involvement of PYK2 proteins in the up-regulation of CD40L and CTLA4 expression and PBMCs proliferation.

Methods
The study protocol was approved by the Human Ethics Review Committee of Shandong Provincial Hospital, Jinan, China. A signed consent form was obtained from each subject prior to study participation.

Subjects
The study subjects were 24 healthy volunteers, 32 RA patients (6 men and 26 women, mean age 42.3 years [range 21-67 years]), and 48 SLE patients (7 men and 41 women, mean age 33.9 years [range 11-69 years]), of whom 12 had inactive SLE disease and 36 had active SLE disease at the time of the study. All patients fulfilled the diagnostic criteria of the American College of Rheumatology for the classification of SLE or RA [36,37]. All SLE patients were admitted to our department between 2006 and 2009, and SLE disease activity was evaluated by the SLE Disease Activity Index (SLEDAI) score[38]. Patients were classified as having inactive disease if the SLEDAI score was persistently ≤9 for at least 3 months prior to the study. Patients with active disease had a SLEDAI score of ≥10 at the time of the study. Ten patients, 9 of whom had newly diagnosed SLE, were receiving no treatment at the time of the study. Thirty-eight SLE patients were receiving low-dose steroids (≤10 mg/day prednisolone) and/or immunosuppressive agents (cyclophosphamide). None of the SLE patients were receiving prednisolone at a dosage of ≥10 mg/day. Twenty-nine patients had biopsy-proven proliferative lupus nephritis (World Health Organization [WHO] class IV [39]), 8 had WHO class II nephritis, 4 had WHO class V nephritis, 7 had WHO class I nephritis, and 6 had central nervous system (CNS) manifestations. The clinical features of patients with and without active SLE are summarized in Table 1. All enrolled patients with RA had ≥6 swollen joints, >6 tender joints, and an erythrocyte sedimentation rate (Westergren) of >30 mm/hour. Twenty-six RA patients were receiving low-dose steroids (≤10 mg/day prednisolone) and/or disease-modifying antirheumatic drugs (methotrexate or sulfasalazine).

Isolation and culture of PBMCs
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers, RA patients, and SLE patients were isolated from 20 ml heparinized peripheral blood by Ficoll-Paque gradient centrifugation (Invitrogen) and then washed twice with phosphate buffered saline (PBS). The viability of PBMCs was >95% as determined by trypan blue staining, and the purity of human T and B lymphocytes isolated was >90% as tested with anti-CD3 mAb and anti-CD19 mAb by flow cytometry. The isolated
PBMCs were divided into two groups: one group was used for Western blotting and Immunocytochemistry; in the other group, the PBMCs were resuspended at 1 × 10^6 PBMC/ml in RPMI-1640 medium supplemented with 10% bovine fetal serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, then cultured with PMA (Sigma) or TyrA9 (Calbiochem) in 24-well culture dishes in 5% CO_2 at 37°C to be used for further testing. Control cultures without stimulants were included in each experiment.

**Western blotting**
Freshly isolated PBMCs, 2 × 10^6, were lysed in 200 μl of cold lysis buffer (1% Triton X-100, 0.5% NP-40, 150 mM NaCl, 10 mM Tris [PH 7.4], 1 mM EDTA, 1 mM EGTA, 0.2 mM Na_3VO_4, 10 mM NaF; 0.2 mM PMSF, and protease inhibitors mixture) and kept on ice on a shaking platform for 30 minutes. After centrifugation at 12000 rpm for 10 minutes, supernatants were transferred to a fresh tube and stored at -80°C. Protein concentrations were determined with the BCA Protein Assay Kit (Santa Cruz Biotechnology, CA, USA). From each sample preparation, 80 μg of total proteins were mixed in Laemmli loading buffer, boiled for 4 minutes, separated by 8% SDS-PAGE and then transferred to PVDF blotting membranes (Gelman, NY, USA). Membranes were blocked with the Tris buffered saline-Tween/1% bovine serum albumin/1% nonfat dry milk and incubated with rabbit polyclonal antibodies specific for PYK2 (SC-9019), phospho-PYK2 (SC-11767-R) and β-actin (SC-1616-R) (All from Santa Cruz Biotechnology, CA, USA) overnight at 4°C (diluted according to the manufacturer’s instructions). Polyclonal PYK2-specific antibody was used to detect the total protein level of PYK2 while phospho-PYK2 (p-PYK2) antibody which specifically recognizes PYK2 phosphorylation on tyrosine 402 to detect the activation of PYK2. β-actin was used as a loading control to assure equal amounts of protein in all lanes. After a final incubation with a 1:5000 dilution of horseradish peroxidase-conjugated secondary antibodies (Zongshan Biotechnology, Beijing, China) for two hours at room temperature, the membranes were developed with an ECL detection system (Santa Cruz CA, USA). For reprobing, the membranes were stripped in 0.2 M glycine (PH 2.5)/0.05% Tween 20 at 80°C for 20 minutes.

**Immunocytochemistry**
Single immunoenzyme staining was performed using the biotin-streptavidin peroxidase method with an LSAB-HRP kit according to the manufacturer’s instructions. Briefly, the freshly isolated PBMCs suspensions were put on glass slides and air-dried for at least 2 h, and either stained immediately or stored at 80°C. After air drying, the cells were fixed/permeablized with cytofix/cytoperm solution for 20 min at 4°C, dried, and washed twice in PBS pH 7.2 for 5 min. The cells were incubated with blocking solution (included in kit) for 5 min in a humid atmosphere prior to the addition of primary antibody specific for phospho-PYK2 (SC-11767-R). Phospho-PYK2 antibody was added at appropriate dilution (1:100) on slides and left for 30 min in a humid atmosphere at room temperature. The cells were subsequently rinsed three times for 3 min in PBS and then allowed to react for 10 min with biotinylated antirabbit antibody (kit component). After a 3-min rinse in PBS and incubation with streptavidin-horseradish peroxidase (LSAB kit) for 30 min, the cells were washed three times in PBS (3 min each). They were then developed in diaminobenzidine, and the reaction was stopped by dipping the slides in distilled water. The cells were counterstained with 1% hematoxylin and covered with coverslips, and then examined under a light micro-

| Characteristic | Patients with active disease | Patients with inactive disease |
|---------------|-----------------------------|-------------------------------|
| No. of men/no. of women | (n = 36) 5/31 | (n = 12) 2/10 |
| Age, mean ± SD (range) years | 35 ± 14 (11–69) | 36 ± 12 (16–59) |
| Disease duration, mean ± SD (range) months | 65 ± 101 (1–260) | 118 ± 98 (5–216) |
| Disease activity | | |
| SLEDAI score (0–105), mean ± SD | 16 ± 4 | 7 ± 4 |
| Anti-dsDNA titer, mean ± SD IU/ml | 597 ± 784 | 49 ± 56 |
| CH50 level, mean ± SD units/ml | 14 ± 11 | 26 ± 8 |
| Clinical manifestation | | |
| WHO class IV nephritis | 24 | 5 |
| Other than WHO class IV nephritis | 12 | 7 |
| CNS disease | 6 | 0 |
| Treatment at time of study | | |
| None | 10 | 0 |
| ≤10 mg/day prednisolone | 28 | 9 |
| Immunosuppressive agents | 7 | 1 |

*Except where indicated otherwise, values are the number of patients.*
scope. Positive cells were counted under ×400 magnification in 10 randomly chosen fields by two independent observers in a blind fashion. The results from these two observers were averaged to obtain the percentages of positive cells per sample.

**Cell staining and flow cytometric analysis**

The cultured PBMCs of each well in suspension were stained with PE-CD40L (TRAP1, BD Biosciences) and PE-CTLA4 (BN13, BD Biosciences) for 15 min at 4°C in the dark, PE-IgG1 was used as a control. After staining, the cells were washed with cold PBS and were immediately analyzed using EPICS XL-4 flow cytometry along with system software (Becton Dickinson, San Jose, CA). The PE fluorescence intensity in PBMCs were measured using an argon laser with an excitation wavelength of 488 nm and emission wavelengths of 575 nm. The PBMCs were tightly gated by volume and complexity on S forward (0°) and side-light scattering (90°) mode. At least 1 × 10⁴ cells were analyzed for each determination.

**Proliferation assays**

For assaying PBMCs proliferation by PYK2 activation, isolated human PBMCs (2 × 10⁵ cells/well) were cultured for 24 h in 96-well flat-bottomed microtitre plates in RPMI 1640 containing 10% FCS, stimulated with PMA or TyrA9 for the indicated duration. The cultures were pulsed with [³H]-thymidine (1.0 μCi/well) 18 h before harvesting the cells, and [³H]-thymidine incorporation was measured in a Microbeta Plus liquid scintillation counter (Wallac, Gaithersburg, MD, USA). Cultures were run in triplicate, and each experiment was repeated at least three times.

**Statistical analysis**

All data were expressed as mean ± standard deviation. A one-way analysis of variance (ANOVA) test was used for comparison of more than two groups. The differences between the groups were assessed with the Post-Hoc Bonferroni test. The analysis of correlations between clinical variables and levels of p-PYK2 was based on Pearson rank test. The level of significance was set to p < 0.05. The data-set was analyzed using the SPSS V 13.0 statistical package. Each experiment was repeated at least 3 times to assess reproducibility.

**Results**

**PYK2 is increased and activated in PBMCs from patients with SLE**

To see the expression pattern and the activation of PYK2 in PBMCs from patients with SLE, we used Western blotting to evaluate the total amount and phosphorylated form of PYK2 in freshly isolated PBMCs from the SLE patients. As controls, PBMCs from healthy donors and RA patients were collected and processed simultaneously. As show in Figure 1A (top blot), the intensity of PYK2 band in PBMCs from SLE patients was higher than those from either healthy controls or patients with RA. Quantitative analysis shows PYK2 in PBMCs from SLE, but not RA patients (0.96 ± 0.34 in RA), was significantly up-regulated (1.13 ± 0.35 and 1.28 ± 0.30) in inactive and active SLE patients, respectively, compared with that from healthy donors (0.94 ± 0.41). Consistently, while PYK2 was weakly phosphorylated on the tyrosine 402 residue in healthy donors and RA patients, a much thicker band corresponding to p-PYK2 was seen in lanes of the SLE patients as shown in Figure 1A (middle blot). This has also been further verified by quantitative analysis in which the level of p-PYK2 was significantly higher in PBMCs from SLE patients (0.97 ± 0.31 for inactive and 1.07 ± 0.33 for active), but not in PBMCs from RA patients (0.81 ± 0.34), compared with normal PBMCs (0.77 ± 0.33) (Figure 1B). The ratio of p-PYK2/PYK2 was exam-
ined and no significant difference was found between SLE patients (0.88 ± 0.19 for inactive SLE and 0.86 ± 0.20 for active SLE), RA patients (0.85 ± 0.21) and healthy donors (0.83 ± 0.18).

To identify in which sub-population of PBMCs the activated PYK2 is expressed, we immunostained phosphorylated PYK2 in PBMCs from the samples mentioned above with an antibody against p-PYK2. As observed in Figure 2, p-PYK2 (2A and 2B) was not detectable in lymphocytes from healthy donors and RA patients, whereas in lymphocytes from SLE patients, both the intensity and the proportion of p-PYK2 immunostaining were increased (2C). These data further confirmed results obtained by Western blotting.

**p-PYK2 is exclusively upregulated in SLE patients with class IV lupus nephritis and negatively correlated with the level of serum complement**

We next assessed the correlation between the levels of p-PYK2 and clinical manifestation of SLE. As shown in Figure 3A and 3B, the expression of p-PYK2 was markedly up-regulated in PBMCs from SLE patients with class IV lupus nephritis, whereas this up-regulation was not seen in either healthy donors or SLE patients with CNS disease or nephritis other than class IV. Next, we analyzed the correlation between the ratio of p-PYK2/PYK2 and lupus nephritis, and no correlation was found for class IV lupus nephritis (data not shown). Furthermore, PYK2 activation and serum complement level (CH50) showed a significant negative correlation (Figure 3C). However, PYK2 activation did not show a correlation with the SLEDAI score (data not show). These results suggest that up-regulation of p-PYK2 in PBMCs is likely to be correlated with class IV nephritis.

**Enhanced PYK2 phosphorylation in PBMCs in response to lymphocyte activation stimulated by PMA**

In vivo, lymphocytes often receive multiple stimuli and become activated to carry out their biologic functions. To understand the molecular events during lymphocyte activation and analyze the role played by PYK2, we tested the effect of PMA on phosphorylation of PYK2. PBMCs obtained from healthy donors, RA and SLE patients were treated with PMA or medium in 24-well culture dishes in 5% CO2 at 37°C for 24 h, and the status of PYK2 Y402 phosphorylation was analyzed by western blotting. As show in Figure 4A, the intensity of p-PYK2 band in PBMCs stimulated by PMA was higher than those stimulated by medium (Figure 4A). Quantitative analysis shows that p-PYK2 in PBMCs stimulated by PMA, but not by medium, was significantly up-regulated in healthy control (1.10 ± 0.32 VS 0.77 ± 0.29), RA (1.12 ± 0.35 VS 0.81 ± 0.30) and SLE (1.47 ± 0.36 VS 1.08 ± 0.34) patients, respectively (Figure 4B). These results indicate that when PBMCs were...
(A) Activation of PYK2 in PBMCs from healthy donors (n = 24) and SLE patients with central nervous system (CNS) disease (n = 6), WHO class IV nephritis (n = 29), or nephritis other than WHO class IV (n = 19).

(B) Total proteins obtained from PBMCs lysates were examined by Western blotting analysis for p-PYK2 as indicated in patients and methods. Lane 1, healthy donors; Lane 2, SLE patients with central nervous system; Lane 3, lupus nephritis other than WHO class IV; Lane 4, lupus nephritis IV.

(B) The ratio between the optical density of specific bands and β-actin of the same sample was calculated and expressed graphically. The experiments for each sample were repeated at least three times and bars represent the mean and standard deviation of three separate experiments. Statistical comparison of all groups was made with healthy donors. The significance level was set at * = P < 0.05.

(C) Correlation between PYK2 activation in PBMCs and serum levels of CH50 in SLE patients (n = 36).

Figure 3

(A) Activation of PYK2 in PBMCs from healthy donors (n = 24) and SLE patients with central nervous system (CNS) disease (n = 6), WHO class IV nephritis (n = 29), or nephritis other than WHO class IV (n = 19). Total proteins obtained from PBMCs lysates were examined by Western blotting analysis for p-PYK2 as indicated in patients and methods. Lane 1, healthy donors; Lane 2, SLE patients with central nervous system; Lane 3, lupus nephritis other than WHO class IV; Lane 4, lupus nephritis IV. (B) The ratio between the optical density of specific bands and β-actin of the same sample was calculated and expressed graphically. The experiments for each sample were repeated at least three times and bars represent the mean and standard deviation of three separate experiments. Statistical comparison of all groups was made with healthy donors. The significance level was set at * = P < 0.05. (C) Correlation between PYK2 activation in PBMCs and serum levels of CH50 in SLE patients (n = 36).
stimulated by PMA, the total level of PYK2 Y402 phosphorylation is enhanced.

**p-PYK2 in PBMCs from SLE patients induces the expression of CD40L and CTLA4**

To further characterize the role of p-PYK2 in lymphocyte activation, we assayed the cell surface costimulatory molecules expression by stimulating or inhibiting PYK2 phosphorylation, using PMA and PYK2 kinase inhibitor TyrA9, respectively. As expected, using PMA to stimulate PBMCs from active SLE resulted in a significant upregulation of CD40L and CTLA4, whereas this upregulation is not observed in PBMCs pretreated with chemical inhibitor of PYK2 kinase activity (Figure 5C). In PBMCs from normal individuals and RA patients, CD40L and CTLA4 expression were also significantly upregulated by stimulation with PMA. This effect, however, cannot be suppressed by administration of TyrA9 (Figure 5A, B). These results suggest that p-PYK2 acts as an important mediator in PMA-induced induction of CD40L and CTLA4 in PBMCs of SLE.

**Discussion**

In this study, we found an upregulation of PYK2 in PBMCs of SLE patients and an activation in SLE with class IV lupus nephritis. We also found the activation is negatively correlated with the level of serum complement. By isolating and culturing the PBMCs, we verified p-PYK2 a mediator specific to SLE to induce costimulatory molecules CD40L and CTLA4, and to promote the cell proliferation. This study represents the first demonstration that PYK2 expression and activation appear exclusive in SLE PBMCs and crucial for the pathogenesis of SLE.

Lymphocyte activation is a fundamental component implicated in the production of autoantibodies in SLE patients. Understanding the precise molecular mechanism of SLE lymphocyte activation will be important to develop novel therapeutic strategies targeting reduction autoantibodies and to increase the sensitivity of current treatment modalities. PYK2, a nonreceptor protein tyrosine kinase which plays pivotal roles in the regulation of lymphocyte activation[33], has drawn our attention in considering the lymphocyte activation in SLE.

Our studies showed no detection of p-PYK2 in PBMCs of RA and healthy controls. PYK2 in SLE PBMCs is not only increased but also phosphorylated at tyrosine 402 resides. These findings suggest that upregulation and activation of PYK2 may be implicated in the pathogenesis of SLE.

**p-PYK2 promotes the proliferation of SLE PBMCs**

To explore whether upregulation of p-PYK2 may contribute to the pathogenesis of SLE, we cultured PBMCs from patients with this condition as well as from those with RA and healthy controls. Cultured cells were subjected to groups in the presence or absence of TyrA9 before stimulated with PMA and the subsequent cell proliferation assay. We found in cultures without TyrA9, the proliferation of PBMCs from all sources were enhanced by PMA. However, in the presence of TyrA9, only PBMCs from SLE patients showed a repressed proliferation when stimulated with PMA (Figure 6). These results indicate p-PYK2 transduces an activation signal for cell proliferation exclusively in PBMCs of SLE.
Up-regulation of CD40L and CTLA-4 by PYK2 activation in PBMCs from patients with active SLE (C), but not those from normal individuals and RA patients (A and B). PBMCs were incubated for 24 h with medium, PMA (1 ng/ml) or pretreated with the PYK2 inhibitor TyrA9 (5 μM) for 1 h before the addition of PMA, and then analyzed for the expression of CD40L and CTLA4 by flow cytometric analysis. All experiments were repeated at least three times with similar results. Statistical analysis: * = p < 0.05.
are likely to play a role in the development and progression of nephritis.

FAK, the prototype of PYK2, mediates signaling in active SLE enhancing autoreactive T cell activation by proliferation and by upregulating the expression of costimulatory molecule CD40L[16]. PYK2 also provides important signals to T and B lymphocyte activation[33,34]. Its expression and activation, however, are not seen in PBMCs from RA patients. We explored whether the similar scenario will happen in SLE. Given that costimulatory molecules are known to be a prerequisite for lymphocyte activation, we answered this question by checking the expression of costimulatory molecules and subsequent proliferation in SLE PBMCs. In contrast to what has been observed in RA, PYK2 was shown exclusively in SLE a mediator of activation signaling of proliferation. Therefore, PYK2-mediated activation of lymphocytes is not only functionally enhanced in SLE but also a process specific to SLE. Taking into account the limitations that chemical inhibitor of Pyk2 kinase activity is almost never perfect in its specificity, in subsequent experiments, we are going to use RNA-mediated interference, Pyk2-deficient PBMCs and dominant negative Pyk2 mutants to confirm the exact function of Pyk2 in regulating SLE PBMCs proliferation.

Abnormal T and B lymphocytes activation and lymphocytes death underlie the pathology of SLE[41]. Potentially autoreactive T and B lymphocytes are removed by apoptosis during development and after completion of an immune response. Paradoxically, lupus T cells exhibit both enhanced spontaneous apoptosis and defective activation-induced cell death [42]. Increased spontaneous apoptosis has been linked to chronic lymphopenia in patients with SLE[42]. By contrast, defective activation-induced cell death (AICD) may be responsible for persistence of autoreactive T and B lymphocytes, leading to expansion of antigen-specific T cell clones[42]. Indeed, in prototypical murine SLE models (i.e., lpr/lpr and gld/gld mice), the animals are defective in Fas and FasL, respectively, which are critical elements in T cell apoptosis. Our result demonstrate that in addition to increased phosphorylation of PYK2 in SLE PBMCs, phosphorylated PYK2 signaling could also enhances the autoreactive lymphocyte activation and proliferation (Fig.5 and Fig.6). However, the mechanism that phosphorylated PYK2 induce lymphocyte proliferation is not clear. It would be interesting to investigate whether phosphorylated PYK2 could promote lymphocyte activation and proliferation via inhibition of apoptosis or via enhanced hyperreactivity of lymphocyte.

Our results, together with those of earlier studies, demonstrate that the PBMCs from SLE patients exhibit both increased activation and enhanced activity of PYK2. We strongly propose PYK2 a major contributor to the complex autoimmune pathogenesis of SLE.

Conclusion

In the present study, We found a significant increase of both the total PYK2 protein and its activated/phosphorylated form in PBMCs from patients with SLE, particularly those with the complication of nephritis (WHO IV). There is a clear inversly correlation between the activation of PYK2 and the level of serum complements. In active SLE patients, activation of PYK2 in PBMCs is accompanying the increased cell proliferation and the induced expression of costimulatory molecules CD40L and CTLA4. These results indicate that phosphorylated PYK2 may induce the expression of CD40L and CTLA4, and subsequently the cell proliferation. PYK2 signaling enhances the autoreactive lymphocyte activation and plays an important role in the pathogenesis of SLE.

Abbreviations

SLE: Systemic lupus erythematosus; FAK: focal adhesion kinase; PYK2: Proline-rich tyrosine kinase2; PBMC: peripheral blood mononuclear cell; RA: rheumatoid arthritis; CPM: [3H]-thymidine incorporation; IL-2: interleukin-2; SLEDAI: SLE Disease Activity Index; WHO:
et al. 9. Wong CK, Lit LC, Tam LS, et al. 8. Koshy M, Berger D, Crow MK: 10. Ueda H, Howson JM, Esposito L, et al. 5. Lenschow DJ, Walunas TL, Bluestone JA: 1. Mills JA: 2. Kotzin BL: 3. Dayal AK, Kammer GM: The T cell enigma in lupus [review]. Arthritis Rheum 1996, 39:23-33. 4. Juang YT, Wang Y, Solomou EE, et al.: Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005, 115:996-1005. 5. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258. 6. Pollard KM, Arnush M, Hultman P, et al.: Costimulation requirements of induced murine systemic autoimmune disease. J Immunol 2004, 173:5880-5887. 7. Y.L. McNerney M, Datta SK: Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000, 165:6627-6634. 8. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996, 98:826-837. 9. Wong CK, Lit LC, Tam LS, et al.: Ablarent production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:989-994. 10. Ueda H, Howson JM, Esposito L, et al.: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511. 11. Mohan C, Shi Y, Laman JD, et al.: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995, 154:1470-1480. 12. Finck BK, Linsley PS, Wosfy D: Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227. 13. Mihara M, Tan I, Chuzhin Y, et al.: CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000, 106:91-101. 14. Horwitz DA, Tang FL, Stimmler MM, et al.: Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: evidence for impaired T cell-accessory cell interaction. Arthritis Rheum 1997, 40:822-833. 15. Kaneko H, Saito K, Hashimoto H, et al.: Preferential elimination of CD28-T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Clin Exp Immunol 1996, 106:218-229. 16. Nakayama S, Saito K, Nakano K, et al.: Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 2007, 56:1559-1568. 17. Nakayama S, Saito K, Fujii K, et al.: J1 integrin-mediated signaling induces inter-cellular adhesion molecule 1 and Fas on rheumatoid synovial cells and Fas-mediated apoptosis. Arthritis Rheum 2003, 48:1239-1248. 18. Shahara S, Castro-Rueda HP, Haines GK, et al.: Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther 2007, 9:R12. 19. Regoli M, Bendayani M: Expression of beta1 integrins in glomerular tissue of Streptococci-induced diabetic rats. Biochem Pharmacol 1999, 77:71-78. 20. Grijelmo C, Rodrigue C, Svrek M, et al.: Pro-invasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathway in colon cancer cells. Cell Signal 2007, 19:1722-1732. 21. Xiang Y, Tan YR, Zhang NS, et al.: Wound repair and proliferation of bronchial epithelial cells regulated by CTNNAL1. J Biochem 2008, 103:920-930. 22. Sasaki H, Nagura K, Ishino M, et al.: Cloning and characterization of cell adhesion kinase(s), a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. Journal of Biological Chemistry 1995, 270:21206-21219. 23. Lev S, Moreno H, Martinez R, et al.: Protein tyrosine kinase PYK2 involved in Ca(2+)−induced regulation of ion channel and MAP kinase functions. Nature 1995, 376:737-745. 24. Ma EA, Lou O, Berg NN, et al.: Cytotoxic T lymphocytes express a beta3 integrin which can induce the phosphorylation of focal adhesion kinase and the related PYK-2. Eur J Immunol 1997, 27:329-335. 25. Rodriguez-Fernandez JL, Sanchez-Martin L, Roy M, et al.: Rho and Rho-associated kinase modulate the tyrosine kinase PYK2 in T-cells through regulation of the activity of the integrin LFA-1. J Biol Chem 2001, 276:240. 26. Dikic I, Schlessinger J: Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J Biol Chem 1998, 273:14. 27. Davis CB, Dikic I, Unutmaz D, et al.: Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 1997, 186:1793-1798. 28. Ganju RK, Brubaker SA, Chernock RD, et al.: Beta-chemokine receptor CCR5 signals through SHPI, SHP2, and Syk. J Biol Chem 2002, 277:157. 29. Berg NN, Ostergaard HL: T cell receptor engagement induces tyrosine phosphorylation of FAK and Pyk2 and their association with Lck. J Immunol 1997, 159:753-757. 30. Ganju RK, Hatch WC, Avraham H, et al.: RAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytes. J Exp Med 1997, 185:1055-1063. 31. Qian D, Lev S, van Oers NS, et al.: Tyrosine phosphorylation of Pyk2 is selectively regulated by Fyn during TCR signaling. J Exp Med 1997, 185:1253-1259. 32. Guinamard R, Okigaki M, Schlessinger J, et al.: Absence of marginal zone B cells in Pyk-2-deficient mice defines its role in the humoral response. J Immunol 2002, 169:919-927. 33. Ostergaard HL, Lysechko TL: Focal adhesion kinase-related protein tyrosine kinase Pyk2 in T-cell activation and function. Immunol Res 2005, 31:267-282. 34. Sancho D, Montoya MC, Nicasias A, et al.: TCR engagement induces proline-rich tyrosine kinase-2 (Pyk2) translocation to the T-cell-APC interface independently of Pyk2 activity and in an immunoreceptor tyrosine based activation motif-mediated fashion. J Immunol 2002, 169:292-300. 35. Gismondi A, Jacobelli J, Mainiero F, et al.: Cutting edge: functional role for proline-rich tyrosine kinase2 in NK cell-mediated natural cytotoxicity. J Immunol 2000, 164:2272-2276. 36. Tan EM, Cohen AS, Fries JF, et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
37. Arnett FC, Edworthy SM, Bloch DA, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
38. Bombardier C, Gladman DD, Urowitz MB, et al.: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992, 35:630-640.
39. Weening JJ, D’Agati VD, Schwartz MM, et al.: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250.
40. Takagi C, Ueki K, Ikeuchi H, et al.: Increased expression of cell adhesion kinase beta in human and rat crescentic glomerulonephritis. Am J Kidney Dis 2002, 39:174-182.
41. Kyttarís VC, Juang YT, Tsokos GC: Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2005, 17:518-522.
42. Perl A, Gergely P Jr, Nagy G, Koncz A, Banki K: Mitochondrial hyperpolarization: a checkpoint of T cell life, death, and autoimmunity. Trends Immunol 2004, 25:360-367.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2474/10/141/prepub